Benjamin A. Schiffman

Array ( [id] => 19798904 [patent_doc_number] => 20250064829 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA [patent_app_type] => utility [patent_app_number] => 18/670375 [patent_app_country] => US [patent_app_date] => 2024-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 108582 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18670375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19642950 [patent_doc_number] => 20240417470 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-19 [patent_title] => FUSIONS WITH CD8 ANTIGEN BINDING MOLECULES FOR MODULATING IMMUNE CELL FUNCTION [patent_app_type] => utility [patent_app_number] => 18/662910 [patent_app_country] => US [patent_app_date] => 2024-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62558 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -71 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18662910 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19403668 [patent_doc_number] => 20240287179 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => REAGENTS AND METHODS FOR TREATING CANCER AND AUTOIMMUNE DISEASE [patent_app_type] => utility [patent_app_number] => 18/594717 [patent_app_country] => US [patent_app_date] => 2024-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34683 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18594717 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19510614 [patent_doc_number] => 20240342300 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => ANTIBODY MOLECULE-DRUG CONJUGATES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/435809 [patent_app_country] => US [patent_app_date] => 2024-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 102478 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18435809 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20466616 [patent_doc_number] => 12522649 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-13 [patent_title] => Antibody purification [patent_app_type] => utility [patent_app_number] => 18/393420 [patent_app_country] => US [patent_app_date] => 2023-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 12980 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 169 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18393420 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20433277 [patent_doc_number] => 12503509 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-23 [patent_title] => CLEC12AxCD3 bispecific antibodies and methods for the treatment of disease [patent_app_type] => utility [patent_app_number] => 18/528535 [patent_app_country] => US [patent_app_date] => 2023-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 45 [patent_no_of_words] => 24782 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 238 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18528535 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19638080 [patent_doc_number] => 12168681 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-17 [patent_title] => Il-2 variants with reduced binding to IL-2 receptor alpha and uses thereof [patent_app_type] => utility [patent_app_number] => 18/494355 [patent_app_country] => US [patent_app_date] => 2023-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 16 [patent_no_of_words] => 19168 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18494355 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19345266 [patent_doc_number] => 20240254229 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => NOVEL DARPin BASED MULTI-SPECIFIC T-CELL ENGAGERS [patent_app_type] => utility [patent_app_number] => 18/492484 [patent_app_country] => US [patent_app_date] => 2023-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 91719 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18492484 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19020212 [patent_doc_number] => 20240076383 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => ANTI-AVB6 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 18/489216 [patent_app_country] => US [patent_app_date] => 2023-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22484 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18489216 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19417417 [patent_doc_number] => 20240293540 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => COMPOSITIONS AND METHODS FOR INCREASING THE SERUM HALF-LIFE OF A THERAPEUTIC AGENT TARGETING COMPLEMENT C5 [patent_app_type] => utility [patent_app_number] => 18/482159 [patent_app_country] => US [patent_app_date] => 2023-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14547 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18482159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19418495 [patent_doc_number] => 20240294618 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => ANTI-VENOM ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/481129 [patent_app_country] => US [patent_app_date] => 2023-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35840 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18481129 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20227222 [patent_doc_number] => 12415865 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-16 [patent_title] => Antibody molecules to C5AR1 and uses thereof [patent_app_type] => utility [patent_app_number] => 18/478846 [patent_app_country] => US [patent_app_date] => 2023-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 79 [patent_no_of_words] => 79865 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18478846 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19020206 [patent_doc_number] => 20240076377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/472920 [patent_app_country] => US [patent_app_date] => 2023-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 97493 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 250 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18472920 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19050940 [patent_doc_number] => 20240092909 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => PD-1 AGONIST ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/466911 [patent_app_country] => US [patent_app_date] => 2023-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11198 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18466911 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19675957 [patent_doc_number] => 12187807 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-07 [patent_title] => Antibody molecules to C5AR1 and uses thereof [patent_app_type] => utility [patent_app_number] => 18/452173 [patent_app_country] => US [patent_app_date] => 2023-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 79 [patent_no_of_words] => 88929 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18452173 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19201526 [patent_doc_number] => 20240173425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => HUMAN CD33 ANTIBODIES AND GLUCOCORTICOID CONJUGATES [patent_app_type] => utility [patent_app_number] => 18/338468 [patent_app_country] => US [patent_app_date] => 2023-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18014 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18338468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19613223 [patent_doc_number] => 20240398903 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-05 [patent_title] => COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION [patent_app_type] => utility [patent_app_number] => 18/329539 [patent_app_country] => US [patent_app_date] => 2023-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34540 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18329539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19065750 [patent_doc_number] => 20240100176 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => HUMAN INTERLEUKIN-4 RECEPTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES [patent_app_type] => utility [patent_app_number] => 18/326461 [patent_app_country] => US [patent_app_date] => 2023-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24684 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18326461 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861883 [patent_doc_number] => 20230416318 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => OSTEOANABOLISM BY 14-3-3ZETA [patent_app_type] => utility [patent_app_number] => 18/314240 [patent_app_country] => US [patent_app_date] => 2023-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10900 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18314240 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18753986 [patent_doc_number] => 20230357343 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => IL-21 POLYPEPTIDES AND TARGETED CONSTRUCTS [patent_app_type] => utility [patent_app_number] => 18/307477 [patent_app_country] => US [patent_app_date] => 2023-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 135633 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18307477 [rel_patent_id] =>[rel_patent_doc_number] =>)